B+
Bull case
20%
Probability
Target price
$8.50
+127.3% vs current
ICU
SeaStar MedicalCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-23
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.40
-9.1% vs current
B-
Bear case
30%
Probability
Target price
$1.00
-73.3% vs current
AI sentiment snapshot
Latest data as of 2026-06-10
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+44.5
Score
AI commentary
The post-print tone is constructive on hospital adds and revenue growth, but the company’s own filings still emphasize recurring losses, working-capital deficiency, and substantial doubt about going concern. No analyst revision data or clean post-release price-reaction datapoint was present in the packet, so this remains a thin-coverage monitoring setup rather than a conviction bull case.
RankAlpha Sentiment Codex - 2026-06-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-14eventQ1 2026 print showed real commercial traction, but still tiny scaleHigh impact
Management reported first-quarter Quellimmune net revenue of about $0.5 million, up 69% year over year, with 7 new hospitals added, a total customer base of 17, and 198 of 339 patients enrolled in the adult NEUTRALIZE-AKI trial. The release also said the company believes it is on track for approximately $2 million of net revenue in 2026, which supports the commercial story but still leaves the business at very small scale [#PR-EARNINGS-2026-05-14] [#SEC-8K-2026-05-13].
2026-09-30catalystGoing-concern and dilution overhang stay the main near-term bear caseHigh impact
The 2026 10-Q says recurring losses, working-capital deficiency, the need for capital to fund operations, and the amount of cash reserve raise substantial doubt about the company’s ability to continue as a going concern. The 2025 10-K carried the same warning, so any capital raise, restructuring, or financing update could matter more than routine operating news [#10-Q-2026-05-13] [#10-K-2026-03-25].
2027-12-31catalystAdult AKI trial enrollment and FDA path remain the long-dated upside leverHigh impact
Management said it is discussing a modular PMA submission and rapid approval pathways with the FDA while continuing to enroll the 339-patient NEUTRALIZE-AKI pivotal trial. If enrollment, site expansion, and regulatory alignment keep advancing, the stock can re-rate on a longer horizon, but this remains a 2027-type payoff with substantial execution risk [#PR-EARNINGS-2026-05-14] [#SEC-8K-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-10 • Updated nightlySource: Internal modelMethodology